Use of novel antiretroviral agents in rescue regimens: a case of early virological failure to raltegravir.
In patients with virological failure during highly active antiretroviral therapy (HAART) and drug resistance, guidelines recommend the achievement of maximal virological suppression by the use of a new regimen with at least 2 active drugs. We describe the clinical outcome of a heavily antiretroviral-experienced patient who experienced early failure to raltegravir.
Tommasi
Chiara
C
National Institute for Infectious Diseases, INMI, L Spallanzani, Rome, Italy.
Ceccherini-Silberstein
Francesca
F
D'Arrigo
Roberta
R
Bellagamba
Rita
R
Tempestilli
Massimo
M
Dessì
Carlo
C
Santoro
Maria M
MM
Forbici
Federica
F
Nicastri
Emanuele
E
Pucillo
Leopoldo P
LP
Perno
Carlo F
CF
Narciso
Pasquale
P
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D011760:Pyrrolidinones / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D016879:Salvage Therapy / Q000379:methods*; D017211:Treatment Failure
D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium